rapiflex MALDI PharmaPulse

rapifleX MALDI PharmaPulse® - Applications

Drug discovery workflow

A million samples per week with rapifleX MALDI PharmaPulse

The new rapifleX MPP is the result of Bruker’s innovative development of MALDI mass spectrometers. It reflects our passion for and knowledge about this technology and its unique applications.  The time-of-flight mass spectrometer (TOF-MS) of the rapifleX MALDI PharmaPulse monitors up to 30 masses in HTS mode: from small molecules to large proteins. The improved resolution and sensitivity of the rapifleX TOF-MS allows e.g. the monitoring of acetylcholine (ACh) and choline to identify acetylcholinesterase (AChE) inhibitors out of millions of substances. An ingenious detector design delivers significantly improved signal to noise ratios for enhanced sensitivity across the mass range. A completely new HTS software suite supports easy set-up of HTS screens, and the proprietary assay development module ensures fast adaption of label-free assays for MALDI mass spectrometry.

rapifleX MALDI Pharma Pulse Acetylcholinesterase
Haslam, C.; Hellicar, J.; Dunn, A.; Fuetterer, A.; Hardy, N.; Marshall, P.; Paape, R.; Pem-berton, M.; Resemann, A.; Leveridge, M. The Evolution of MALDI-TOF Mass Spectrometry toward Ultra-High-Through¬put Screening: 1536-Well Format and Beyond. J. Biomol. Screen. 2015, 1-11.

Automation of rapifleX MALDI PharmaPulse

The rapifleX MALDI PharmaPulse is designed to seamlessly integrate with laboratory automation systems to perform fully automatic screening campaigns. The MALDI PharmaPulse software solution offers an open interface to control parts of its operation from external scheduling software (e.g. Analytik Jena lab automation, HighRes Biosolutions, Beckman Coulter, Thermo Scientific automation). The new high speed autoloader of the rapifleX MPP works hand in hand with robot systems for quick loading and unloading of sample plates.

rapifleX MALDI Pharma Pulse automation

Fail Early, Fail Fast

Can the ultra-high-speed capability of the MPP to screen for hits accelerate the discovery of drug-like small molecules or biological therapeutics? Bringing a drug to market can take more than 12 years and can easily cost more than $1B dollars. Most new chemical entities fail to make it because they are either toxic or they do not work. Of the million compounds or more that are screened, 5,000 to 10,000 compounds go through the lead optimization process, resulting in about 250 compounds making it to the pre-clinical process. From this stage, about 5 make it to the critical clinical trials process, with usually only 1 compound potentially makes it to market.